Precedent Wealth Partners LLC Buys 1,881 Shares of The Clorox Company $CLX

Precedent Wealth Partners LLC raised its stake in shares of The Clorox Company (NYSE:CLX) by 20.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 11,303 shares of the company’s stock after acquiring an additional 1,881 shares during the period. Precedent Wealth Partners LLC’s holdings in Clorox were worth $1,357,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Raymond James Financial Inc. lifted its stake in Clorox by 15.6% during the 1st quarter. Raymond James Financial Inc. now owns 269,926 shares of the company’s stock valued at $39,747,000 after acquiring an additional 36,352 shares during the period. OneDigital Investment Advisors LLC bought a new position in Clorox during the 1st quarter valued at about $247,000. Brown Miller Wealth Management LLC bought a new position in Clorox during the 1st quarter valued at about $399,000. Roman Butler Fullerton & Co. bought a new position in Clorox during the 1st quarter valued at about $400,000. Finally, Wedge Capital Management L L P NC lifted its stake in Clorox by 33.5% during the 1st quarter. Wedge Capital Management L L P NC now owns 28,510 shares of the company’s stock valued at $4,198,000 after acquiring an additional 7,159 shares during the period. Institutional investors own 78.53% of the company’s stock.

Clorox Trading Up 0.9%

Clorox stock opened at $123.30 on Friday. The firm has a 50 day moving average of $122.81 and a 200 day moving average of $129.64. The firm has a market capitalization of $15.08 billion, a price-to-earnings ratio of 18.91, a P/E/G ratio of 0.98 and a beta of 0.52. The Clorox Company has a 12-month low of $116.53 and a 12-month high of $171.37. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX) last released its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.63. The company had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.82 EPS. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, research analysts predict that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox’s dividend payout ratio (DPR) is 76.07%.

Insider Transactions at Clorox

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer directly owned 54,221 shares of the company’s stock, valued at $6,711,475.38. This trade represents a 21.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.57% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Citigroup reiterated a “neutral” rating and issued a $135.00 price objective (down previously from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. Zacks Research upgraded shares of Clorox from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Wells Fargo & Company lowered their price objective on shares of Clorox from $130.00 to $125.00 and set an “equal weight” rating on the stock in a research note on Thursday, September 25th. Morgan Stanley lowered their price objective on shares of Clorox from $150.00 to $137.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st. Finally, Barclays lowered their price objective on shares of Clorox from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Clorox has an average rating of “Reduce” and an average target price of $134.08.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.